An elderly patient died in a clinical study of Roche Holding AG’s experimental treatment for Alzheimer’s disease, prompting ...

Roche Holding has one of the most promising treatments for Alzheimer’s in clinical trials. The drug is several years away ...

Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...

In an investor presentation, executives hinted at the possibility of seeking an accelerated approval of trontinemab if it can ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer’s ...

Two blood tests currently in development have shown 'very high accuracy' in detecting tell-tale signs of Alzheimer's disease, ...

Roche Holding AG said its third-quarter sales rose thanks to eye drug Vabysmo as well as medicines for cancer, hemophilia and ...

He also reported relationships with Epitech, Roche, Novo Nordisk, and PIAM Farmaceutici ... trial of repetitive TMS of the ...